{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enzalutamide+tablet",
    "query": {
      "intervention": "Enzalutamide tablet"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 46,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enzalutamide+tablet&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-13T06:23:50.418Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04191096",
      "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Hormone-Sensitive Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Androgen Deprivation Therapy (ADT)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1251,
      "start_date": "2020-02-12",
      "completion_date": "2026-04-08",
      "has_results": true,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-09-13T06:23:50.418Z",
      "location_count": 27,
      "location_summary": "Anchorage, Alaska • Duarte, California • Los Angeles, California + 22 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04191096"
    },
    {
      "nct_id": "NCT04237584",
      "title": "A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Enzalutamide during Lead-in Period",
          "type": "DRUG"
        },
        {
          "name": "Lead-in Enzalutamide followed by Radium-223/Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Lead-in Enzalutamide followed by Placebo/Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Darolutamide during Lead-in Period",
          "type": "DRUG"
        },
        {
          "name": "Lead-in Darolutamide followed by Radium-223/Darolutamide",
          "type": "DRUG"
        },
        {
          "name": "Lead-in Darolutamide followed by Placebo/Darolutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MANA RBM",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 23,
      "start_date": "2020-06-30",
      "completion_date": "2022-03-07",
      "has_results": true,
      "last_update_posted_date": "2022-10-07",
      "last_synced_at": "2026-09-13T06:23:50.418Z",
      "location_count": 1,
      "location_summary": "Myrtle Beach, South Carolina",
      "locations": [
        {
          "city": "Myrtle Beach",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04237584"
    },
    {
      "nct_id": "NCT03170960",
      "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "Renal Cell Carcinoma",
        "Non-Small Cell Lung Cancer",
        "Castration-resistant Prostate Cancer",
        "Triple Negative Breast Cancer",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Hepatocellular Carcinoma",
        "Gastric Cancer",
        "Gastroesophageal Junction Adenocarcinoma",
        "Colorectal Cancer",
        "Head and Neck Cancer",
        "Differentiated Thyroid Cancer",
        "Lower Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 914,
      "start_date": "2017-09-05",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-17",
      "last_synced_at": "2026-09-13T06:23:50.418Z",
      "location_count": 57,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03170960"
    },
    {
      "nct_id": "NCT02438007",
      "title": "A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Galeterone",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LTN PHARMACEUTICALS, INC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 953,
      "start_date": "2015-06",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2023-03-15",
      "last_synced_at": "2026-09-13T06:23:50.418Z",
      "location_count": 51,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 42 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02438007"
    },
    {
      "nct_id": "NCT05546268",
      "title": "Study of Oral MRT-2359 in Selected Cancer Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "NSCLC",
        "SCLC",
        "High Grade Neuroendocrine Cancer",
        "DLBCL",
        "L-MYC and N-MYC Amplified Solid Tumors",
        "NSCLC With High or Low L-MYC or N-MYC Expression",
        "HR-positive, HER2-negative Breast Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Oral MRT-2359",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Monte Rosa Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 174,
      "start_date": "2022-10-12",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-03-03",
      "last_synced_at": "2026-09-13T06:23:50.418Z",
      "location_count": 17,
      "location_summary": "Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 13 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Lawrence",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05546268"
    },
    {
      "nct_id": "NCT04221542",
      "title": "Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "AMG 509",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 479,
      "start_date": "2020-03-04",
      "completion_date": "2032-03-21",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-09-13T06:23:50.418Z",
      "location_count": 25,
      "location_summary": "Duarte, California • Fullerton, California • San Francisco, California + 22 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04221542"
    },
    {
      "nct_id": "NCT01605227",
      "title": "Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer",
        "Castration Resistant Prostate Cancer",
        "Pain",
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1028,
      "start_date": "2012-07",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2018-03-14",
      "last_synced_at": "2026-09-13T06:23:50.418Z",
      "location_count": 77,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 73 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01605227"
    },
    {
      "nct_id": "NCT06922318",
      "title": "The COSMYC Trial (COmbined Suppression of MYC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "ZEN-3694",
          "type": "DRUG"
        },
        {
          "name": "Testosterone cypionate",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Luteinizing hormone-releasing hormone (LHRH) analogue",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 50,
      "start_date": "2025-08-19",
      "completion_date": "2031-08-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-09-13T06:23:50.418Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06922318"
    },
    {
      "nct_id": "NCT05588609",
      "title": "Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NSCLC Harboring NRG1 Fusion",
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Afatinib Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide Pill",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone acetate tablets",
          "type": "DRUG"
        },
        {
          "name": "MCLA-128",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Partner Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2022-11-17",
      "completion_date": "2025-07-03",
      "has_results": false,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-09-13T06:23:50.418Z",
      "location_count": 7,
      "location_summary": "Whittier, California • Lake Mary, Florida • Bethesda, Maryland + 4 more",
      "locations": [
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05588609"
    },
    {
      "nct_id": "NCT02286921",
      "title": "Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration Resistant Metastatic Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Testosterone cypionate",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Testosterone Enanthate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "MALE",
        "summary": "18 Years to 80 Years · Male only"
      },
      "enrollment_count": 222,
      "start_date": "2015-01",
      "completion_date": "2020-02-21",
      "has_results": true,
      "last_update_posted_date": "2020-11-06",
      "last_synced_at": "2026-09-13T06:23:50.418Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Duarte, California • Aurora, Colorado + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02286921"
    }
  ]
}